Clinical Trial Update: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Bintrafusp alfa in combination with Pimasertib for brain metastases has been terminated, with results posted in March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer
• Cutaneous Melanoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bintrafusp alfa (bintrafusp alfa)
• Pimasertib (pimasertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-03-18